BioInvent International (STO:BINV)46% objective response rate (6 of 13 evaluable patients) and a 92% disease control rate (12 of 13) in relapsed/refractory CTCLImmune activation confirmed by CD8+ T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback